Intravascular Identification and Drug-Eluting Balloon Treatment of Vulnerable Lipid-Rich Plaques

NCT04765956 | Unknown DMC FDA Device

• 1 other identifier: DEBuT-LRP
• Study Type: interventional
• Target: 40
• Locations: 1 country
• Sites: 1

Brief Summary

Rationale: Two-thirds of intracoronary thrombi causing acute coronary syndrome (ACS) result from rupture of lipid-rich plaques (LRP). After treatment of the culprit lesion in ACS patients, additional LRPs are found in approximately 50% of patients. Near infrared spectroscopy (NIRS) combined with intracoronary ultrasound (IVUS) can identify these vulnerable plaques during coronary angiography (CAG) and is able to assess plaque characteristics and the lipid-core burden index in a 4mm segment (LCBImm4). It is currently unknown whether treatment of LRPs leads to plaque stabilization, potentially reducing the number of subsequent ACS. We hypothesize that LRPs can be treated with balloons coated with an antiproliferative drug (i.e. drug-eluting balloons; DEB) to deliver selective pharmacotherapeutic treatment to halt the local atherosclerotic process and subsequently reduce the risk for atherosclerotic events. Objectives: To determine the change in plaque characteristics of non-culprit LRPs, as measured with IVUS/NIRS, after treatment with DEB in patients with ACS. Study design: Prospective single-arm clinical trial Study population: Patients with non-ST-elevation acute coronary syndromes Intervention: If a LRP is detected with IVUS/NIRS, it will be treated with DEB. In case multiple LRPs are detected, only one will be treated. Main study endpoints: The difference in LCBImm4 between baseline and 9 months of plaques treated with DEB.

Conditions

Coronary Artery Disease

Keywords

Lipid-rich plaque; Non-ST-elevation myocardial infarction; Near-infrared spectroscopy; Drug-eluting balloon

Outcome Measures

Primary Outcomes (1)

• LCBImm4 difference of DEB-treated LRPs

  The difference in LCBImm4 between baseline and 9 months follow-up of lipid-rich plaques treated with drug-eluting balloon, as measured with near-infrared spectroscopy (NIRS).

  9 months

Secondary Outcomes (7)

• The change in lipid-core burden index in a 4 mm segment (LCBImm4) as measured with IVUS + NIRS from baseline to 9 month follow-up in identified additional LRPs that are not treated with DEB.

  9 months

• Rate of flow-limiting dissections necessitating bail-out stent implantation;

  9 months

• Rate of periprocedural myocardial infarction;

  9 months

• Rate of LRP lesion failure (defined as cardiac death, myocardial infarction, or ischemia-driven revascularization related to an identified non-culprit LRP lesion up to one-year follow-up);

  1 year

• Patient-oriented composite outcomes, defined as all-cause mortality, myocardial infarction, or any repeat revascularization up to one-year follow-up;

  1 year

Study Arms (1)

Drug-eluting balloon treatment

EXPERIMENTAL

Drug-eluting balloon (DEB) treatment of lipid-rich plaque

Device: Drug-eluting balloon treatment

Interventions

Drug-eluting balloon treatment DEVICE

Drug-eluting balloon (DEB) treatment of lipid-rich plaque

Drug-eluting balloon treatment

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Patient has an acute coronary syndrome without ST-segment elevation on the ECG (NSTE-ACS), including non-ST-elevation myocardial infarction and unstable angina pectoris, defined according to the Fourth Universal Definition of Myocardial Infarction.
• An invasive revascularization strategy for NSTE-ACS with PCI is chosen.

You may not qualify if:

• Previous coronary artery bypass-grafting;
• Presence of a chronic total occlusion;
• Too many (complex) coronary lesions requiring staged PCI procedure(s);
• Procedural complication of the index PCI;
• Unstable patients (the presence of cardiogenic shock, need for intubation, need for inotropes);
• Patients with ST-segment elevations on the ECG requiring immediate primary PCI;
• Body weight \> 250 kg;
• Known renal insufficiency (estimated Glomerular Filtration Rate \[eGFR\] \<30 mL/min/1.73m2 or subject on dialysis);
• Hypersensitivity or allergy to contrast with inability to properly pre-hydrate;
• Presence of a comorbid condition with a life expectancy of less than one year;
• Participation in another trial;
• Subject is belonging to a vulnerable population (per investigator's judgment, e.g., subordinate hospital staff) or is unable to read or write.

Sponsors & Collaborators

• Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA): lead

Study Sites (1)

Amsterdam UMC, location AMC

Amsterdam, 1105AZ, Netherlands

RECRUITING

MeSH Terms

Conditions

Coronary Artery Disease; Non-ST Elevated Myocardial Infarction

Condition Hierarchy (Ancestors)

Coronary Disease; Myocardial Ischemia; Heart Diseases; Cardiovascular Diseases; Arteriosclerosis; Arterial Occlusive Diseases; Vascular Diseases; Myocardial Infarction; Infarction; Ischemia; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Necrosis

Central Study Contacts

Jose Henriques

CONTACT

+31205669111; j.p.henriques@amsterdamumc.nl

Anna van Veelen

CONTACT

a.vanveelen@amsterdamumc.nl

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Prof. Dr.

Model Details: Prospective single-arm clinical trial

Study Record Dates

• First Submitted: February 18, 2021
• First Posted: February 23, 2021
• Study Start: January 19, 2021
• Primary Completion: September 9, 2023
• Study Completion: September 9, 2023
• Last Updated: February 1, 2023

Record last verified: 2023-01

Locations

NL (1)